Alteogen Inc
KOSDAQ:196170
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Geely Automobile Holdings Ltd
HKEX:175
|
HK |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (54), the stock would be worth ₩449 500.02 (22% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 44.3 | ₩369 000 |
0%
|
| 3-Year Average | 54 | ₩449 500.02 |
+22%
|
| 5-Year Average | 23.1 | ₩192 506.92 |
-48%
|
| Industry Average | 4.6 | ₩37 964.79 |
-90%
|
| Country Average | 1.1 | ₩9 336.81 |
-97%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
|
Alteogen Inc
KOSDAQ:196170
|
19.7T KRW | 44.3 | 139.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | -107.4 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 21.4 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 7.1 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 5.9 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 2.5 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 6.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 2.3 | 30.7 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 0.7 |
| Median | 1.1 |
| 70th Percentile | 2.3 |
| Max | 2 461.2 |
Other Multiples
Alteogen Inc
Glance View
In the bustling hub of South Korea's biotech industry, Alteogen Inc. has carved out a distinctive niche with its innovative approach to drug development. Founded in 2008, this company has harnessed the power of advanced biotechnology to specialize in the development of biopharmaceuticals, particularly focusing on creating long-acting protein therapeutics and biobetters. Alteogen's flagship technology, ALT-P7, a proprietary platform for producing antibody-drug conjugates, exemplifies how the company blends scientific ingenuity with commercial acumen. By reimagining existing biological drugs known as biobetters, Alteogen leverages its proprietary technologies to improve the efficacy and delivery of these treatments, promising enhanced convenience and therapeutic outcomes for patients. Financially, Alteogen thrives through both strategic partnerships and its own product pipeline. The company secures revenue by licensing its technology platforms to global pharmaceutical giants, thereby earning milestone payments and royalties. Additionally, Alteogen's ongoing research and development efforts continuously expand its portfolio, particularly in biosimilars—biological products highly similar to already-approved reference products. This dual-pronged approach, combining its proprietary biotechnological innovations with robust strategic alliances, positions Alteogen not just as a player but as an innovator in the biopharmaceutical sector, with the potential for significant impact in the realm of chronic disease treatment.
